Bristol Myers Squibb (CELG-RI) Net Margin (2009 - 2026)

Bristol Myers Squibb has disclosed Net Margin across 18 years of filings, most recently posting 23.32% for Q1 2026.

• In Q1 2026, Net Margin rose 134.0% year-over-year to 23.32%; the TTM figure through Mar 2026 stood at 15.0% (up 382.0% YoY), while the FY2025 annual figure was 14.64%, up 3314.0% from the prior year.
• Net Margin grew to 23.32% in Q1 2026, from 8.69% in the prior quarter.
• Over the last five years, Net Margin for CELG-RI reached as high as 23.32% in Q1 2026 and fell as low as 100.36% in Q1 2024.
• The 5-year median for Net Margin is 14.33% (2022), against an average of 7.77%.
• Annual changes were most pronounced in 2024 — Net Margin slumped 12036 bps — and 2025, when it surged 12234 bps.
• A 5-year view of Net Margin shows it stood at 17.75% in 2022, then decreased by 16 bps to 14.87% in 2023, then plunged by 96 bps to 0.62% in 2024, then soared by 1311 bps to 8.69% in 2025, then soared by 168 bps to 23.32% in 2026.
• According to Business Quant data, Net Margin over the past three periods registered 23.32%, 8.69%, and 17.96% for Q1 2026, Q4 2025, and Q3 2025 respectively.